

# Jens D Lundgren

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1869606/jens-d-lundgren-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

447  
papers

34,936  
citations

82  
h-index

178  
g-index

478  
ext. papers

40,522  
ext. citations

7.2  
avg, IF

6.63  
L-index

#	Paper	IF	Citations
447	Identifying patients with chronic lymphocytic leukemia without need of treatment (CLL-WONT): end of endless watch and wait?. <i>European Journal of Haematology</i> , <b>2022</b> ,	3.8	2
446	Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.. <i>Lancet, The</i> , <b>2022</b> ,	40	6
445	Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting.. <i>Open Forum Infectious Diseases</i> , <b>2022</b> , 9, ofac029	1	1
444	Characteristics Associated with Serological Covid-19 Vaccine Response and Durability in an Older Population with Significant Comorbidity: The Danish Nationwide ENFORCE Study.. <i>Clinical Microbiology and Infection</i> , <b>2022</b> ,	9.5	3
443	Increased Prevalence of Liver Fibrosis in People Living With Human Immunodeficiency Virus Without Viral Hepatitis Compared to Population Controls. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 224, 443-452	7.52	4
442	Measles, Mumps, Rubella, and Varicella Zoster Virus Serology and Infections in Solid Organ Transplant Recipients During the First Year Posttransplantation. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e3733-e3739	11.6	2
441	29. Sustained Recovery in Patients Admitted to Hospital With COVID-19. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, S20-S21	1	
440	Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.. <i>Annals of Internal Medicine</i> , <b>2021</b> ,	8	13
439	Clostridioides difficile infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study. <i>Transplant Infectious Disease</i> , <b>2021</b> , e13770	2.7	
438	Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 779453	8.4	9
437	The association of human leukocyte antigen alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies. <i>Aids</i> , <b>2021</b> , 35, 783-789	3.5	0
436	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e2323-e2333	11.6	5
435	Effect of Changes in Body Mass Index on the Risk of Cardiovascular Disease and Diabetes Mellitus in HIV-Positive Individuals: Results From the D:A:D Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2021</b> , 86, 579-586	3.1	2
434	ABO blood types and sepsis mortality. <i>Annals of Intensive Care</i> , <b>2021</b> , 11, 61	8.9	1
433	Phylogenetic analysis of HIV-1 shows frequent cross-country transmission and local population expansions. <i>Virus Evolution</i> , <b>2021</b> , 7, veab055	3.7	
432	Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19-a randomised double-blinded placebo-controlled trial. <i>European Respiratory Journal</i> , <b>2021</b> ,	13.6	11
431	Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, 2031-2036	11.6	20

430	Bacterial and fungal bloodstream infections in solid organ transplant recipients: results from a Danish cohort with nationwide follow-up. <i>Clinical Microbiology and Infection</i> , <b>2021</b> ,	9.5	1
429	Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study. <i>International Journal of Infectious Diseases</i> , <b>2021</b> , 108, 370-376	10.5	3
428	Pulmonary Arterial Enlargement in Well-Treated Persons With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 223, 94-100	7	
427	The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D Study. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 223, 632-637	7	1
426	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 905-914	59.2	203
425	Identification of two different coagulation phenotypes in people living with HIV with undetectable viral replication. <i>Scientific Reports</i> , <b>2021</b> , 11, 4383	4.9	1
424	Causes and outcomes of hospitalizations among people living with HIV in GeorgiaB referral institution, 2012-2017. <i>International Journal of STD and AIDS</i> , <b>2021</b> , 32, 662-670	1.4	
423	Genome-wide association study of high-sensitivity C-reactive protein, D-dimer, and interleukin-6 levels in multiethnic HIV+ cohorts. <i>Aids</i> , <b>2021</b> , 35, 193-204	3.5	0
422	Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2021</b> , 86, 248-257	3.1	1
421	Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. <i>Journal of the International AIDS Society</i> , <b>2021</b> , 24, e25690	5.4	1
420	Development and Dynamics of Cytomegalovirus UL97 Ganciclovir Resistance Mutations in Transplant Recipients Detected by Next-Generation Sequencing. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab462	1	0
419	23. Development and Validation of a Risk Score for Post-transplant Lymphoproliferative Disorders among Solid Organ Transplant Recipients. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, S15-S16	1	
418	Abdominal Adipose Tissue Is Associated With Alterations in Tryptophan-Kynurenine Metabolism and Markers of Systemic Inflammation in People With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 221, 419-427	7	6
417	Prevalence and Risk Factors of Moderate-to-Severe Hepatic Steatosis in Human Immunodeficiency Virus Infection: The Copenhagen Co-morbidity Liver Study. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 222, 1353-1362 <sup>8</sup>	7	
416	Tuberculosis among Patients Undergoing Solid Organ Transplantation or Dialysis in a Low-Endemic Country, 2004-2017. <i>Tuberculosis Research and Treatment</i> , <b>2020</b> , 2020, 7636975	2.1	2
415	Mortality and admission to intensive care units after febrile neutropenia in patients with cancer. <i>Cancer Medicine</i> , <b>2020</b> , 9, 3033-3042	4.8	7
414	Preoperative TruCulture <sup>®</sup> whole blood cytokine response predicts post-operative inflammation in pancreaticoduodenectomy patients-A pilot cohort study. <i>Scandinavian Journal of Immunology</i> , <b>2020</b> , 92, e12930	3.4	5
413	Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2020</b> , 83, 240-250	3.1	15

412	Machine learning can identify newly diagnosed patients with CLL at high risk of infection. <i>Nature Communications</i> , <b>2020</b> , 11, 363	17.4	36
411	Interstitial Lung Abnormalities in People With HIV Infection and Uninfected Controls. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 221, 1973-1977	7	6
410	Pericardial Adipose Tissue Volume Is Independently Associated With Human Immunodeficiency Virus Status and Prior Use of Stavudine, Didanosine, or Indinavir. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 222, 54-61	7	4
409	Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa470	1	1
408	252. Increased incidence rates of positive blood cultures shortly after chemotherapy treatment initiation among individuals treated for solid malignant tumours. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, S125-S126	1	
407	1075. Absolute Lymphocyte Count as a Predictor of Cytomegalovirus (CMV) Infection and Recurrence in Hematopoietic Stem Cell Transplant (HSCT) Recipients. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, S565-S565	1	
406	1079. The Risk of Cytomegalovirus (CMV) Infection and Recurrence Among Solid Organ Transplant Recipients. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, S567-S568	1	
405	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. <i>PLoS ONE</i> , <b>2020</b> , 15, e0243625	3.7	0
404	Remdesivir for the Treatment of Covid-19 - Final Report. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1813-1826	59.2	3562
403	Impact of Human Immunodeficiency Virus-Related Gut Microbiota Alterations on Metabolic Comorbid Conditions. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, e359-e367	11.6	21
402	Fraction of Exhaled Nitric Oxide Levels Are Elevated in People Living With Human Immunodeficiency Virus Compared to Uninfected Controls, Suggesting Increased Eosinophilic Airway Inflammation. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 3214-3221	11.6	4
401	Epidemiology of hepatitis E virus infection in a cohort of 4023 immunocompromised patients. <i>International Journal of Infectious Diseases</i> , <b>2020</b> , 91, 188-195	10.5	6
400	Evaluation of an electronic, patient-focused management system aimed at preventing cytomegalovirus disease following solid organ transplantation. <i>Transplant Infectious Disease</i> , <b>2020</b> , 22, e13252	2.7	9
399	Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 222, 1103-1107	7	51
398	Case Report: Hyper IgM Syndrome Identified by Whole Genome Sequencing in a Young Syrian Man Presenting With Atypical, Severe and Recurrent Mucosal Leishmaniasis. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 567856	8.4	1
397	Development and validation of a cycle-specific risk score for febrile neutropenia during chemotherapy cycles 2-6 in patients with solid cancers: The FENCE score. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 321-328	7.5	6
396	Poor Concordance Between Liver Stiffness and Noninvasive Fibrosis Scores in HIV Infection Without Viral Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 3049-3050	6.9	0
395	2569. The Gut Microbiome and Acute Graft vs. Host Disease Risk in Hematopoietic Stem Cell Transplantation Recipients. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S892-S893	1	78

394	Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study. <i>EclinicalMedicine</i> , <b>2019</b> , 13, 91-100	11.3	7
393	Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial. <i>Journal of Infectious Diseases</i> , <b>2019</b> , 220, 1325-1334	7	11
392	Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. <i>American Journal of Epidemiology</i> , <b>2019</b> , 188, 1569-1577	3.8	45
391	Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacteremia (SAB7): study protocol for a randomized controlled trial. <i>Trials</i> , <b>2019</b> , 20, 250	2.8	7
390	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. <i>Lancet, The</i> , <b>2019</b> , 393, 2428-2438	40	363
389	Biomarker-assisted identification of sepsis-related acute liver impairment: a frequent and deadly condition in critically ill patients. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2019</b> , 57, 1422-1431	5.9	5
388	Incidence Rates and Risk Factors of Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofz086	1	10
387	Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 650-657	11.6	14
386	The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined Analysis. <i>Journal of Infectious Diseases</i> , <b>2019</b> , 219, 254-263	7	9
385	Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 1420-1426	11.6	69
384	Long-lasting alterations in adipose tissue density and adiponectin production in people living with HIV after thymidine analogues exposure. <i>BMC Infectious Diseases</i> , <b>2019</b> , 19, 708	4	5
383	Increased Risk of Anemia, Neutropenia, and Thrombocytopenia in People With Human Immunodeficiency Virus and Well-Controlled Viral Replication. <i>Journal of Infectious Diseases</i> , <b>2019</b> , 220, 1834-1842	7	6
382	Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. <i>Journal of Infectious Diseases</i> , <b>2019</b> , 220, 1629-1634	7	5
381	Immune function as predictor of infectious complications and clinical outcome in patients undergoing solid organ transplantation (the ImmuneMo:SOT study): a prospective non-interventional observational trial. <i>BMC Infectious Diseases</i> , <b>2019</b> , 19, 573	4	3
380	Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study. <i>Journal of the International AIDS Society</i> , <b>2019</b> , 22, e25297	5.4	13
379	Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofz215	1	10
378	2613. The Epidemiology of Respiratory Syncytial Virus (RSV) in People with Immune Dysfunction Seen at a Tertiary Hospital Between 2010 and 2017. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S908-S909	1	78
377	2670. Clostridioides difficile Infection (CDI) in Solid-Organ (SOT) and Hematopoietic Stem Cell Transplant (HCT) Recipients: A Prospective Multinational Study. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S936-S936	1	78

376	Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm <sup>3</sup> : Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2019</b> , 81, 10-17	3.1	8
375	Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe. <i>Aids</i> , <b>2019</b> , 33, 2013-2024	3.5	11
374	Serious clinical events in HIV-positive persons with chronic kidney disease. <i>Aids</i> , <b>2019</b> , 33, 2173-2188	3.5	5
373	Prevalence and risk factors of prolonged QT interval and electrocardiographic abnormalities in persons living with HIV. <i>Aids</i> , <b>2019</b> , 33, 2205-2210	3.5	10
372	Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors. <i>Aids</i> , <b>2019</b> , 33, 675-683	3.5	25
371	Risk factors for antiretroviral therapy (ART) discontinuation in a large multinational trial of early ART initiators. <i>Aids</i> , <b>2019</b> , 33, 1385-1390	3.5	2
370	A Large-Cohort, Longitudinal Study Determines Precancer Disease Routes across Different Cancer Types. <i>Cancer Research</i> , <b>2019</b> , 79, 864-872	10.1	8
369	Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study. <i>Leukemia</i> , <b>2019</b> , 33, 662-670	10.7	19
368	Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. <i>Lancet HIV,the</i> , <b>2019</b> , 6, e116-e127	7.8	53
367	Serious Non-AIDS Conditions in HIV: Benefit of Early ART. <i>Current HIV/AIDS Reports</i> , <b>2018</b> , 15, 162-171	5.9	9
366	Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study. <i>Journal of the International AIDS Society</i> , <b>2018</b> , 21, e25083	5.4	7
365	Higher Risk of Abdominal Obesity, Elevated Low-Density Lipoprotein Cholesterol, and Hypertriglyceridemia, but not of Hypertension, in People Living With Human Immunodeficiency Virus (HIV): Results From the Copenhagen Comorbidity in HIV Infection Study. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 573-581	11.6	49
364	Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial. <i>Lancet HIV,the</i> , <b>2018</b> , 5, e172-e180	7.8	23
363	Airflow limitation in people living with HIV and matched uninfected controls. <i>Thorax</i> , <b>2018</b> , 73, 431-438	7.3	36
362	No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts. <i>Aids</i> , <b>2018</b> , 32, 985-997	3.5	11
361	Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. <i>Lancet HIV,the</i> , <b>2018</b> , 5, e146-e154	7.8	45
360	Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 598-607	9.7	7
359	Induced hypothermia in patients with septic shock and respiratory failure (CASS): a randomised, controlled, open-label trial. <i>Lancet Respiratory Medicine,the</i> , <b>2018</b> , 6, 183-192	35.1	29



358	Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 405-413	1.6	2
357	Prevention of HIV transmission by antiretroviral therapy. <i>Lancet HIV,the</i> , <b>2018</b> , 5, e108-e109	7.8	3
356	Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. <i>Lancet HIV,the</i> , <b>2018</b> , 5, e291-e300	7.8	105
355	Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 217, 405-412	7	10
354	Abacavir use and risk of recurrent myocardial infarction. <i>Aids</i> , <b>2018</b> , 32, 79-88	3.5	12
353	Cytomegalovirus Viral Load in Bronchoalveolar Lavage to Diagnose Lung Transplant Associated CMV Pneumonia. <i>Transplantation</i> , <b>2018</b> , 102, 326-332	1.8	24
352	Language used to convey HIV infection risk is important - AuthorsPreply. <i>Lancet HIV,the</i> , <b>2018</b> , 5, e272	7.8	
351	Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America. <i>BMC Infectious Diseases</i> , <b>2018</b> , 18, 191	4	3
350	Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 341-349	11.6	6
349	Computed tomography quantification of emphysema in people living with HIV and uninfected controls. <i>European Respiratory Journal</i> , <b>2018</b> , 52,	13.6	8
348	The association between detected drug resistance mutations and CD4 T-cell decline in HIV-positive individuals maintained on a failing treatment regimen. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 105-116	1.6	1
347	Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015. <i>Eurosurveillance</i> , <b>2018</b> , 23,	19.8	8
346	Contemporary protease inhibitors and cardiovascular risk. <i>Current Opinion in Infectious Diseases</i> , <b>2018</b> , 31, 8-13	5.4	18
345	Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?. <i>Aids</i> , <b>2018</b> , 32, 205-215	3.5	3
344	Brief Report: Prevalence of Peripheral Artery Disease Is Higher in Persons Living With HIV Compared With Uninfected Controls. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2018</b> , 79, 381-385	3.1	16
343	Development and Validation of a Risk Score for Febrile Neutropenia After Chemotherapy in Patients With Cancer: The FENCE Score. <i>JNCI Cancer Spectrum</i> , <b>2018</b> , 2, pky053	4.6	14
342	Impact of CMV PCR Blips in Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation. <i>Transplantation Direct</i> , <b>2018</b> , 4, e355	2.3	7
341	Association of Suboptimal Antiretroviral Therapy Adherence With Inflammation in Virologically Suppressed Individuals Enrolled in the SMART Study. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, ofx275	1	12

340	Classification of death causes after transplantation (CLASS): Evaluation of methodology and initial results. <i>Medicine (United States)</i> , <b>2018</b> , 97, e11564	1.8	6
339	Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations. <i>Aids</i> , <b>2018</b> , 32, 2807-2819	3.5	8
338	Febrile Neutropenia and Long-term Risk of Infection Among Patients Treated With Chemotherapy for Malignant Diseases. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, ofy255	1	8
337	Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. <i>Aids</i> , <b>2018</b> , 32, 1995-2004	3.5	12
336	Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort. <i>Aids</i> , <b>2018</b> , 32, 2405-2416	3.5	43
335	Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D: A: D Cohort Analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2018</b> , 78, 579-588	3.1	18
334	Predicting recovery from acute kidney injury in critically ill patients: development and validation of a prediction model. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , <b>2018</b> , 20, 54-60	2.8	6
333	Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per $\mu$ l: secondary outcome results from a randomised controlled trial. <i>Lancet HIV</i> , <b>2017</b> , 4, e105-e112	7.8	34
332	Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals. <i>Aids</i> , <b>2017</b> , 31, 1261-1270	3.5	15
331	Late presentation of chronic viral hepatitis for medical care: a consensus definition. <i>BMC Medicine</i> , <b>2017</b> , 15, 92	11.4	28
330	Endothelial Damage Signals Refractory Acute Kidney Injury in Critically Ill Patients. <i>Shock</i> , <b>2017</b> , 47, 696-701	3.1	12
329	Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	31
328	Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 64, 1413-1421	11.6	43
327	Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. <i>PLoS Medicine</i> , <b>2017</b> , 14, e1002424	11.6	12
326	Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009-2015. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, ofx212	1	9
325	Induced Hypothermia in Patients with Septic Shock and Ventilator-demanding Respiratory Failure. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, S30-S30	1	78
324	Are we successfully managing cardiovascular disease in people living with HIV?. <i>Current Opinion in HIV and AIDS</i> , <b>2017</b> , 12, 594-603	4.2	10
323	Incidental lung cancers and positive computed tomography images in people living with HIV. <i>Aids</i> , <b>2017</b> , 31, 1973-1977	3.5	4



322	Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 64, 87-91	11.6	439
321	Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, ofx262	1	44
320	Neuropeptides and Airway Macromolecule Secretion <b>2017</b> , 447-464		
319	An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. <i>European Journal of Preventive Cardiology</i> , <b>2016</b> , 23, 214-23	3.9	127
318	Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial. <i>Annals of Intensive Care</i> , <b>2016</b> , 6, 114	8.9	13
317	Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 316, 171-81	27.4	780
316	Predictive value of prostate specific antigen in a European HIV-positive cohort: does one size fit all?. <i>Antiviral Therapy</i> , <b>2016</b> , 21, 529-534	1.6	4
315	Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study. <i>Antiviral Therapy</i> , <b>2016</b> , 21, 495-506	1.6	15
314	The cardiovascular risk management for people living with HIV in Europe: how well are we doing?. <i>Aids</i> , <b>2016</b> , 30, 2505-2518	3.5	25
313	Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, 821-829	11.6	35
312	Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. <i>BMC Medicine</i> , <b>2016</b> , 14, 61	11.4	84
311	Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 214, 73-9	7	8
310	Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. <i>Lancet HIV,the</i> , <b>2016</b> , 3, e120-31	7.8	42
309	Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. <i>Lancet HIV,the</i> , <b>2016</b> , 3, e23-32	7.8	129
308	A Method to Estimate the Size and Characteristics of HIV-positive Populations Using an Individual-based Stochastic Simulation Model. <i>Epidemiology</i> , <b>2016</b> , 27, 247-56	3.1	5
307	Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy. <i>PLoS ONE</i> , <b>2016</b> , 11, e0155100	3.7	107
306	Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?. <i>Aids</i> , <b>2016</b> , 30, 1629-375		8
305	Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. <i>Aids</i> , <b>2016</b> , 30, 1583-96	3.5	8

304	Associations between HIV-RNA-based indicators and virological and clinical outcomes. <i>Aids</i> , <b>2016</b> , 30, 1961-72	3.5	8
303	Copenhagen comorbidity in HIV infection (COCOMO) study: a study protocol for a longitudinal, non-interventional assessment of non-AIDS comorbidity in HIV infection in Denmark. <i>BMC Infectious Diseases</i> , <b>2016</b> , 16, 713	4	42
302	The per-protocol effect of immediate versus deferred antiretroviral therapy initiation. <i>Aids</i> , <b>2016</b> , 30, 2659-2663	3.5	18
301	Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3, ofw009	1	16
300	Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 214, 408-16	7	73
299	Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: The D:A:D Study. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 214, 1212-20	7	28
298	Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. <i>PLoS Medicine</i> , <b>2015</b> , 12, e1001809	11.6	107
297	Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 795-807	59.2	1791
296	When is the best time to initiate antiretroviral therapy?. <i>Lancet HIV,the</i> , <b>2015</b> , 2, e312-3	7.8	1
295	Profound endothelial damage predicts impending organ failure and death in sepsis. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2015</b> , 41, 16-25	5.3	56
294	Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?. <i>Liver International</i> , <b>2015</b> , 35, 2384-91	7.9	27
293	Invasive <i>Candida</i> infections and the harm from antibacterial drugs in critically ill patients: data from a randomized, controlled trial to determine the role of ciprofloxacin, piperacillin-tazobactam, meropenem, and cefuroxime. <i>Critical Care Medicine</i> , <b>2015</b> , 43, 594-602	1.4	27
292	Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2015</b> , 68, 568-77	3.1	31
291	The Vancouver Consensus: antiretroviral medicines, medical evidence, and political will. <i>Lancet, The</i> , <b>2015</b> , 386, 505-7	40	22
290	Mild induced hypothermia: effects on sepsis-related coagulopathy--results from a randomized controlled trial. <i>Thrombosis Research</i> , <b>2015</b> , 135, 175-82	8.2	9
289	Thrombocytopenia and cancer risk during HIV infection. <i>Aids</i> , <b>2015</b> , 29, 1425-7	3.5	
288	Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. <i>Aids</i> , <b>2015</b> , 29, 1855-62	3.5	43
287	Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals. <i>Aids</i> , <b>2015</b> , 29, 1205-15	3.5	37

286	HIV resistance testing and detected drug resistance in Europe. <i>Aids</i> , <b>2015</b> , 29, 1379-89	3.5	12
285	Projected Lifetime Healthcare Costs Associated with HIV Infection. <i>PLoS ONE</i> , <b>2015</b> , 10, e0125018	3.7	41
284	Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America. <i>PLoS ONE</i> , <b>2015</b> , 10, e0145380	3.7	13
283	Factors Associated With Plasma IL-6 Levels During HIV Infection. <i>Journal of Infectious Diseases</i> , <b>2015</b> , 212, 585-95	7	86
282	Sustainable HIV treatment in Africa through viral-load-informed differentiated care. <i>Nature</i> , <b>2015</b> , 528, S68-76	50.4	118
281	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. <i>Eurosurveillance</i> , <b>2015</b> , 20,	19.8	55
280	Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe. <i>Journal of Infection</i> , <b>2014</b> , 68, 259-63	18.9	31
279	Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naïve populations beginning treatment: modelling study and economic analysis. <i>Lancet HIV, the</i> , <b>2014</b> , 1, e85-93	7.8	33
278	Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. <i>Lancet, The</i> , <b>2014</b> , 384, 241-8	40	622
277	Update on HIV in Western Europe. <i>Current HIV/AIDS Reports</i> , <b>2014</b> , 11, 177-85	5.9	19
276	Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. <i>BMC Nephrology</i> , <b>2014</b> , 15, 51	2.7	6
275	Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: results from the Strategies for Management of Antiretroviral Therapy [SMART] Study. <i>Journal of Electrocardiology</i> , <b>2014</b> , 47, 264-71	1.4	3
274	Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study. <i>Journal of Clinical Virology</i> , <b>2014</b> , 60, 295-300	14.5	20
273	Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. <i>Aids</i> , <b>2014</b> , 28, 187-99	3.5	50
272	Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis. <i>Aids</i> , <b>2014</b> , 28, 577-87	3.5	10
271	Deteriorating renal function and clinical outcomes in HIV-positive persons. <i>Aids</i> , <b>2014</b> , 28, 727-37	3.5	20
270	Major challenges in clinical management of TB/HIV co-infected patients in Eastern Europe compared with Western Europe and Latin America. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19505	5.4	6
269	Potential future impact of a partially effective HIV vaccine in a southern African setting. <i>PLoS ONE</i> , <b>2014</b> , 9, e107214	3.7	16

268	Determinants of IL-6 levels during HIV infection. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 1948-54	4	6
267	The prevalence and predictive value of dipstick urine protein in HIV-positive persons in Europe. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 1956-61	5.4	1
266	Elevation in Liver Transaminase (ALT-flares) in Transplant (TX) Recipients: Risk factors and Consequences. <i>Open Forum Infectious Diseases</i> , <b>2014</b> , 1, S26-S26	1	
265	Roundtable discussion: how lessons learned from HIV can inform the global response to viral hepatitis. <i>BMC Infectious Diseases</i> , <b>2014</b> , 14 Suppl 6, S18	4	5
264	HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective. <i>BMC Infectious Diseases</i> , <b>2014</b> , 14 Suppl 6, S13	4	17
263	Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 210, 234-43	7	38
262	Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation. <i>Aids</i> , <b>2014</b> , 28 Suppl 1, S15-23	3.5	39
261	Relationship between inflammatory and coagulation biomarkers and cardiac autonomic function in HIV-infected individuals. <i>Biomarkers in Medicine</i> , <b>2014</b> , 8, 1073-83	2.3	8
260	Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe. <i>European Respiratory Journal</i> , <b>2014</b> , 43, 166-77	13.6	25
259	People with HIV are at increased risk of acute myocardial infarction. <i>Evidence-based Nursing</i> , <b>2014</b> , 17, 43-4	0.3	
258	Antiretroviral therapy recommendations for the global community: aspiration versus reality. <i>Aids</i> , <b>2014</b> , 28, 939-41	3.5	3
257	Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons. <i>Current Opinion in HIV and AIDS</i> , <b>2014</b> , 9, 41-7	4.2	15
256	Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. <i>Aids</i> , <b>2014</b> , 28, 1791-6	3.5	18
255	Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. <i>Aids</i> , <b>2014</b> , 28, 2565-71	3.5	9
254	Antiretroviral dose reduction: good for patients and rollout. <i>Lancet, The</i> , <b>2014</b> , 383, 1442-1443	4.0	2
253	Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. <i>PLoS ONE</i> , <b>2014</b> , 9, e87160	3.7	28
252	Factors associated with D-dimer levels in HIV-infected individuals. <i>PLoS ONE</i> , <b>2014</b> , 9, e90978	3.7	49
251	Outcomes of influenza A(H1N1)pdm09 virus infection: results from two international cohort studies. <i>PLoS ONE</i> , <b>2014</b> , 9, e101785	3.7	30

250	Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings. <i>PLoS ONE</i> , <b>2014</b> , 9, e109148	3.7	22
249	Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. <i>The Lancet Global Health</i> , <b>2013</b> , 2, 23-34	13.6	160
248	When to start antiretroviral therapy: the need for an evidence base during early HIV infection. <i>BMC Medicine</i> , <b>2013</b> , 11, 148	11.4	25
247	Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 57, 112-21	11.6	45
246	Are antiretrovirals enough for people living with HIV?. <i>Lancet, The</i> , <b>2013</b> , 382, 1466-7	4.0	1
245	Electrocardiographic spatial QRS-T angle and incident cardiovascular disease in HIV-infected patients (from the Strategies for the Management of Antiretroviral Therapy [SMART] study). <i>American Journal of Cardiology</i> , <b>2013</b> , 111, 118-24	3	5
244	Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. <i>Clinical Trials</i> , <b>2013</b> , 10, S5-S36	2.2	87
243	CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. <i>Aids</i> , <b>2013</b> , 27, 907-918	3.5	12
242	Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. <i>Aids</i> , <b>2013</b> , 27, 407-15	3.5	84
241	Associations between immune depression and cardiovascular events in HIV infection. <i>Aids</i> , <b>2013</b> , 27, 2735-48	3.5	44
240	TB meningitis in HIV-positive patients in Europe and Argentina: clinical outcome and factors associated with mortality. <i>BioMed Research International</i> , <b>2013</b> , 2013, 373601	3	7
239	Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). <i>PLoS Medicine</i> , <b>2013</b> , 10, e1001510	11.6	212
238	Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. <i>Journal of Infectious Diseases</i> , <b>2013</b> , 207, 1359-69	7	236
237	The natural history of HIV infection. <i>Current Opinion in HIV and AIDS</i> , <b>2013</b> , 8, 311-7	4.2	37
236	Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, 870-9	11.6	38
235	The incidence of AIDS-defining illnesses at a current CD4 count $\geq 200$ cells/ $\mu$ l in the post-combination antiretroviral therapy era. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 57, 1038-47	11.6	79
234	Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings. <i>Journal of Infectious Diseases</i> , <b>2013</b> , 207 Suppl 2, S57-62	7	54
233	Further research needed to support a policy of antiretroviral therapy as an HIV prevention initiative. <i>Antiviral Therapy</i> , <b>2013</b> , 18, 285-7	1.6	5

232	Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. <i>Aids</i> , <b>2013</b> , 27, 1433-41	3.5	119
231	Platelet count kinetics following interruption of antiretroviral treatment. <i>Aids</i> , <b>2013</b> , 27, 59-68	3.5	11
230	Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: the D: A: D study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2013</b> , 63, 456-63	3.1	13
229	Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. <i>BMC Infectious Diseases</i> , <b>2013</b> , 13, 471	4	58
228	Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfecting patients. <i>PLoS ONE</i> , <b>2013</b> , 8, e64283	3.7	17
227	Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study). <i>PLoS ONE</i> , <b>2013</b> , 8, e52845	3.7	111
226	Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. <i>PLoS ONE</i> , <b>2013</b> , 8, e55312	3.7	169
225	The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies. <i>PLoS ONE</i> , <b>2013</b> , 8, e57121	3.7	41
224	The potential of antimicrobials to induce thrombocytopenia in critically ill patients: data from a randomized controlled trial. <i>PLoS ONE</i> , <b>2013</b> , 8, e81477	3.7	14
223	Dampening the effect of drug resistance in HIV: a leap forward. <i>Lancet Infectious Diseases</i> , <b>2012</b> , 12, 91-2	25.5	3
222	Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study. <i>BMC Infectious Diseases</i> , <b>2012</b> , 12, 229	4	8
221	Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methods. <i>BMC Public Health</i> , <b>2012</b> , 12, 296	4.1	28
220	Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study. <i>PLoS ONE</i> , <b>2012</b> , 7, e41673	3.7	24
219	Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. <i>PLoS ONE</i> , <b>2012</b> , 7, e40245	3.7	54
218	Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring. <i>PLoS ONE</i> , <b>2012</b> , 7, e42834	3.7	14
217	Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. <i>PLoS ONE</i> , <b>2012</b> , 7, e44454	3.7	383
216	Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. <i>Journal of the International AIDS Society</i> , <b>2012</b> , 15, 17426	5.4	50
215	HIV therapies and the kidney: some good, some not so good?. <i>Current HIV/AIDS Reports</i> , <b>2012</b> , 9, 111-20	5.9	11



214	Projected life expectancy of people with HIV according to timing of diagnosis. <i>Aids</i> , <b>2012</b> , 26, 335-43	3.5	298
213	Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial. <i>BMJ Open</i> , <b>2012</b> , 2, e000635	3	62
212	HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2012</b> , 60, 128-34	3.1	20
211	Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. <i>Aids</i> , <b>2012</b> , 26, 315-23	3.5	25
210	System to classify cause of deaths in HIV-positive persons: time to harmonize. <i>Aids</i> , <b>2012</b> , 26, 1835-6	3.5	5
209	The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 1291-300	1.6	8
208	Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. <i>Aids</i> , <b>2012</b> , 26, 1917-26	3.5	56
207	Prevention of HIV-1 infection with antiretroviral therapy. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 1934; author reply 1935	59.2	32
206	The metabolic syndrome in HIV. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 25, 479-86	6.5	22
205	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. <i>Lancet Infectious Diseases</i> , <b>2011</b> , 11, 363-71	25.5	292
204	Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDA. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 781-5	1.6	1
203	Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. <i>Aids</i> , <b>2011</b> , 25, 367-77	3.5	51
202	Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. <i>Aids</i> , <b>2011</b> , 25, 1305-15	3.5	142
201	Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. <i>Aids</i> , <b>2011</b> , 25, 1497-504	3.5	36
200	Hepatitis delta in HIV-infected individuals in Europe. <i>Aids</i> , <b>2011</b> , 25, 1987-92	3.5	59
199	Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2011</b> , 56, 36-43	3.1	129
198	Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. <i>Critical Care Medicine</i> , <b>2011</b> , 39, 2048-58	1.4	275
197	Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors. <i>Aids</i> , <b>2011</b> , 25, 1505-13	3.5	16

196	The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. <i>Epidemiology</i> , <b>2011</b> , 22, 516-23	3.1	111
195	A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study. <i>HIV Clinical Trials</i> , <b>2011</b> , 12, 109-17		26
194	Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings. <i>Aids</i> , <b>2011</b> , 25, 843-50	3.5	70
193	Haemoglobin and anaemia in the SMART study. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 329-37	1.6	12
192	Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART Study. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 667-75	1.6	15
191	Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study. <i>Journal of Electrocardiology</i> , <b>2011</b> , 44, 779-85	1.4	38
190	Factors associated with the development of cytomegalovirus infection following solid organ transplantation. <i>Scandinavian Journal of Infectious Diseases</i> , <b>2011</b> , 43, 360-5		17
189	Cardiovascular implications from untreated human immunodeficiency virus infection. <i>European Heart Journal</i> , <b>2011</b> , 32, 945-51	9.5	59
188	A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 204, 741-52	7	16
187	Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score. <i>PLoS ONE</i> , <b>2011</b> , 6, e25665	3.7	5
186	Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health. <i>Clinical Trials</i> , <b>2010</b> , 7, 705-18	2.2	20
185	Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 201, 318-30	7	479
184	Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2010</b> , 65, 548-55	5.1	45
183	Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , <b>2010</b> , 17, 491-501		253
182	Rescue of severely immunocompromised HIV-positive persons. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 202, 1467-9	7	1
181	Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. <i>Aids</i> , <b>2010</b> , 24, 1667-78	3.5	307
180	Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2010</b> , 55, 262-70	3.1	203
179	Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. <i>Archives of Internal Medicine</i> , <b>2010</b> , 170, 410-9		35

178	Dialysis and renal transplantation in HIV-infected patients: a European survey. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2010</b> , 55, 582-9	3.1	39
177	High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. <i>Aids</i> , <b>2010</b> , 24, 427-35	3.5	67
176	Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. <i>Aids</i> , <b>2010</b> , 24, 857-65	3.5	47
175	Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. <i>Antiviral Therapy</i> , <b>2010</b> , 15, 563-70	1.6	9
174	Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. <i>Aids</i> , <b>2010</b> , 24, 1537-48	3.5	332
173	HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. <i>Antiviral Therapy</i> , <b>2010</b> , 15, 1077-86	1.6	33
172	Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. <i>Cancer</i> , <b>2010</b> , 116, 5306-15	6.4	104
171	Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. <i>Journal of Infectious Diseases</i> , <b>2009</b> , 200, 687-97	7	52
170	Use of risk equations for predicting disease progression in HIV infection. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 48, 951-3	11.6	4
169	Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. <i>Journal of Infectious Diseases</i> , <b>2009</b> , 200, 973-83	7	120
168	Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study. <i>Diabetes Care</i> , <b>2009</b> , 32, 474-80	14.6	28
167	Cost-effectiveness of strategies for monitoring the response to antiretroviral therapy in resource-limited settings. <i>Archives of Internal Medicine</i> , <b>2009</b> , 169, 904; author reply 904-5		2
166	Uncertainty as to whether the use of antiretroviral therapy for persons recently infected with HIV has a favorable risk-to-benefit ratio. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 48, 1162; author reply 1162-3	11.6	4
165	Reply to Pascual Pareja et al.. <i>Journal of Infectious Diseases</i> , <b>2009</b> , 199, 1557-1557	7	1
164	Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). <i>Circulation</i> , <b>2009</b> , 119, 805-11	16.7	79
163	Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. <i>Aids</i> , <b>2009</b> , 23, 2485-95	3.5	30
162	Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. <i>Aids</i> , <b>2009</b> , 23, 1689-99	3.5	53
161	Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 1065-74	1.6	74

160	Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2009</b> , 50, 457-63	3.1	47
159	Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. <i>Lancet, The</i> , <b>2008</b> , 371, 1417-26	4.0	687
158	Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. <i>Lancet, The</i> , <b>2008</b> , 371, 1443-51	4.0	147
157	Monitoring of antiretroviral therapy in low-resource settings [AuthorsPreply]. <i>Lancet, The</i> , <b>2008</b> , 372, 289	4.0	2
156	Abacavir and increased risk of myocardial infarction [AuthorsPreply]. <i>Lancet, The</i> , <b>2008</b> , 372, 804-805	4.0	12
155	Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART. <i>Scandinavian Journal of Infectious Diseases</i> , <b>2008</b> , 40, 908-13		1
154	Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. <i>Aids</i> , <b>2008</b> , 22, 2187-98	3.5	30
153	Incidence of pancreatitis in HIV-infected patients, and the association with antiretroviral therapy. <i>Aids</i> , <b>2008</b> , 22, 997-8	3.5	5
152	HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. <i>Aids</i> , <b>2008</b> , 22, 2143-53	3.5	180
151	Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. <i>Aids</i> , <b>2008</b> , 22, 2279-89	3.5	54
150	Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2008</b> , 48, 324-33	3.1	42
149	Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 197, 1145-55	7	162
148	Impact of bacteremia on the pathogenesis of experimental pneumococcal meningitis. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 197, 235-44	7	30
147	Opportunistic disease and mortality in patients coinfecting with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. <i>Clinical Infectious Diseases</i> , <b>2008</b> , 47, 1468-75	11.6	48
146	Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2008</b> , 178, 630-6	10.2	82
145	Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 198, 1337-44	7.44	127
144	Guidelines for managing cardiovascular risk: an evolving area. <i>Current Opinion in HIV and AIDS</i> , <b>2008</b> , 3, 205-6	4.2	4
143	The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. <i>Aids</i> , <b>2008</b> , 22, 47-56	3.5	35

142	Response to combination antiretroviral therapy: variation by age. <i>Aids</i> , <b>2008</b> , 22, 1463-73	3.5	173
141	Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. <i>Aids</i> , <b>2008</b> , 22, 367-76	3.5	37
140	Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?. <i>Aids</i> , <b>2008</b> , 22, 2381-90	3.5	26
139	Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. <i>PLoS Medicine</i> , <b>2008</b> , 5, e203	11.6	1179
138	The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients. <i>BMC Infectious Diseases</i> , <b>2008</b> ,	4	30
137	In vivo study of experimental pneumococcal meningitis using magnetic resonance imaging. <i>BMC Medical Imaging</i> , <b>2008</b> , 8, 1	2.9	19
136	The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe--a review of published results. <i>Central European Journal of Public Health</i> , <b>2008</b> , 16, 99-105	1.2	13
135	ART failure and strategies for switching ART regimens in Europe. <i>Central European Journal of Public Health</i> , <b>2008</b> , 16, 141-4	1.2	
134	Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 177-87	1.6	90
133	Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 399-407	1.6	7
132	Interruption of Antiretroviral Therapy and Risk of Cardiovascular Disease in Persons with HIV-1 Infection: Exploratory Analyses from the SMART Trial. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 177-188	1.6	125
131	Modelled in vivo HIV Fitness under drug Selective Pressure and Estimated Genetic Barrier Towards Resistance are Predictive for Virological Response. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 399-408	1.6	11
130	Incidence of abacavir hypersensitivity reactions in EuroSIDA. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 687-696	1.6	11
129	Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count $\geq$ 300 cells/microL who were assigned to 7.5 MIU interleukin-2. <i>HIV Medicine</i> , <b>2007</b> , 8, 112-23	2.7	6
128	Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2007</b> , 101, 339-44	3.1	9
127	Class of antiretroviral drugs and the risk of myocardial infarction. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 1723-35	59.2	1179
126	A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. <i>International Journal of Epidemiology</i> , <b>2007</b> , 36, 1309-18	7.8	17
125	Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 196, 1180-90	7	11

124	When should antiretroviral therapy for HIV be started?. <i>BMJ, The</i> , <b>2007</b> , 334, 76-8	5.9	51
123	Clinical outcomes in clinical trials of anti-HIV treatment. <i>Future HIV Therapy</i> , <b>2007</b> , 1, 251-258		1
122	Chronic renal failure among HIV-1-infected patients. <i>Aids</i> , <b>2007</b> , 21, 1119-27	3.5	155
121	Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. <i>Aids</i> , <b>2007</b> , 21, 1867-75	3.5	34
120	Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. <i>Aids</i> , <b>2007</b> , 21, 721-32	3.5	67
119	The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. <i>Aids</i> , <b>2007</b> , 21, 2033-42	3.5	13
118	Meta-analysis of procalcitonin for sepsis detection. <i>Lancet Infectious Diseases, The</i> , <b>2007</b> , 7, 499-500; author reply 502-3	25.5	4
117	Risk of Discontinuation of Nevirapine due to Toxicities in Antiretroviral-Naive and -Experienced HIV-Infected patients with High and Low CD4+ T-cell Counts. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 325-334	1.6	17
116	Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2006</b> , 42, 229-37	3.1	32
115	Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study. <i>Journal of Infectious Diseases</i> , <b>2006</b> , 194, 633-41	7	63
114	Limited but increasing use of treatment for hepatitis C across Europe in patients coinfecting with HIV and hepatitis C. <i>Scandinavian Journal of Infectious Diseases</i> , <b>2006</b> , 38, 1092-7		13
113	Evaluation of anti-pneumococcal capsular antibodies as adjunctive therapy in experimental pneumococcal meningitis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2006</b> , 58, 1291-4	5.1	3
112	Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. <i>Archives of Internal Medicine</i> , <b>2006</b> , 166, 1632-41		869
111	HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. <i>Lancet, The</i> , <b>2006</b> , 368, 451-8	4.0	187
110	The CD4 lymphocyte count and risk of clinical progression. <i>Current Opinion in HIV and AIDS</i> , <b>2006</b> , 1, 43-94.2		47
109	Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. <i>Aids</i> , <b>2006</b> , 20, 1141-50	3.5	34
108	Issues in the design of trials comparing management strategies for heavily pretreated patients. <i>Current Opinion in HIV and AIDS</i> , <b>2006</b> , 1, 476-81	4.2	1
107	Influence of the blood bacterial load on the meningeal inflammatory response in <i>Streptococcus pneumoniae</i> meningitis. <i>BMC Infectious Diseases</i> , <b>2006</b> , 6, 78	4	12



106	The impact of antiretroviral therapy on AIDS and survival. <i>Journal of HIV Therapy</i> , <b>2006</b> , 11, 36-8		11
105	Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from An Inter-Cohort Analysis. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 567-574	1.6	25
104	HIV-1 Subtypes and Response to Combination Antiretroviral Therapy in Europe. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 707-716	1.6	36
103	Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. <i>Aids</i> , <b>2005</b> , 19, 593-601	3.5	390
102	Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?. <i>Aids</i> , <b>2005</b> , 19, 2117-25	3.5	92
101	Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. <i>Journal of Infectious Diseases</i> , <b>2005</b> , 192, 992-1002	7	319
100	Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. <i>Journal of Hepatology</i> , <b>2005</b> , 42, 615-24	13.4	302
99	Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. <i>Vaccine Journal</i> , <b>2005</b> , 12, 491-6		133
98	Commentary: Death in the era of potent antiretroviral therapy: shifting causes, new challenges. <i>International Journal of Epidemiology</i> , <b>2005</b> , 34, 130-1	7.8	4
97	Impact of coinfection with HIV-1 and GB virus C in patients receiving a ritonavir-boosted HAART regimen: a substudy to the MaxCmin1 trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2005</b> , 40, 378-80	3.1	6
96	Blocking of leukocyte accumulation in the cerebrospinal fluid augments bacteremia and increases lethality in experimental pneumococcal meningitis. <i>Journal of Neuroimmunology</i> , <b>2005</b> , 166, 126-31	3.5	30
95	Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression. <i>Scandinavian Journal of Infectious Diseases</i> , <b>2005</b> , 37, 890-901		25
94	Decline in esophageal candidiasis and use of antimycotics in European patients with HIV. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 1446-54	0.7	23
93	Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 779-90	1.6	5
92	A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 735-743	1.6	30
91	Predictors of Hypertension and Changes of Blood Pressure in HIV-Infected Patients. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 811-823	1.6	68
90	Are Specific Antiretrovirals associated with an Increased Risk of Discontinuation due to Toxicities or Patient/Physician Choice in patients with Hepatitis C Virus Coinfection?. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 779-790	1.6	11
89	Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 791-802	1.6	40

88	Current epidemiology of <i>Pneumocystis pneumonia</i> . <i>Emerging Infectious Diseases</i> , <b>2004</b> , 10, 1713-20	10.2	309
87	Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 190, 148-55	7	50
86	Starting highly active antiretroviral therapy: why, when and response to HAART. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2004</b> , 54, 10-3	5.1	22
85	Attenuation of the bacterial load in blood by pretreatment with granulocyte-colony-stimulating factor protects rats from fatal outcome and brain damage during <i>Streptococcus pneumoniae</i> meningitis. <i>Infection and Immunity</i> , <b>2004</b> , 72, 4647-53	3.7	33
84	Foscarnet used in salvage therapy of HIV-1 patients harbouring multiple nucleotide excision mutations. <i>Aids</i> , <b>2004</b> , 18, 1076-8	3.5	13
83	Changing incidence of central nervous system diseases in the EuroSIDA cohort. <i>Annals of Neurology</i> , <b>2004</b> , 55, 320-8	9.4	231
82	The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. <i>Cancer</i> , <b>2004</b> , 100, 2644-54	6.4	108
81	Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. <i>Scandinavian Journal of Infectious Diseases</i> , <b>2004</b> , 36, 14-9		54
80	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet, The</i> , <b>2004</b> , 364, 51-62	4.0	267
79	Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. <i>Aids</i> , <b>2004</b> , 18, 1795-804	3.5	22
78	Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. <i>Aids</i> , <b>2004</b> , 18, 2333-7	3.5	27
77	Clinical trial methodology and clinical cohorts: the importance of complete follow-up in trials evaluating the virological efficacy of anti-HIV medicines. <i>Current Opinion in Infectious Diseases</i> , <b>2004</b> , 17, 33-7	5.4	4
76	Anemia and survival in human immunodeficiency virus. <i>Clinical Infectious Diseases</i> , <b>2003</b> , 37 Suppl 4, S297-303	11.0	44
75	Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. <i>Aids</i> , <b>2003</b> , 17, 2045-52	3.5	55
74	Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. <i>Aids</i> , <b>2003</b> , 17, 831-40	3.5	47
73	Cardiovascular disease risk factors in HIV patients: Association with antiretroviral therapy. Results from the DAD study. <i>Aids</i> , <b>2003</b> , 17, 1179-1193	3.5	645
72	Combination antiretroviral therapy and the risk of myocardial infarction. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 1993-2003	59.2	1336
71	Virological rebound after suppression on highly active antiretroviral therapy. <i>Aids</i> , <b>2003</b> , 17, 1741-51	3.5	83

70	Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. <i>Journal of Infectious Diseases</i> , <b>2003</b> , 188, 635-42	7	108
69	Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. <i>Aids</i> , <b>2003</b> , 17, 1179-93	3.5	312
68	Changes in Viral Load in People with Virological Failure who Remain on the Same Haart Regimen. <i>Antiviral Therapy</i> , <b>2003</b> , 8, 127-136	1.6	18
67	A Randomized Trial Comparing Initial Haart Regimens of Nelfinavir/Nevirapine and Ritonavir/Saquinavir in Combination with Two Nucleoside Reverse Transcriptase Inhibitors. <i>Antiviral Therapy</i> , <b>2003</b> , 8, 595-602	1.6	6
66	The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. <i>Contemporary Clinical Trials</i> , <b>2002</b> , 23, 198-220		74
65	YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. <i>Vaccine Journal</i> , <b>2002</b> , 9, 598-604		45
64	Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 186, 189-97	7	48
63	A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 185, 178-87	7	108
62	Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. <i>Annals of Internal Medicine</i> , <b>2002</b> , 137, 239-50	8	98
61	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. <i>Lancet, The</i> , <b>2002</b> , 360, 119-29	40	1246
60	Analysis of Virological Efficacy in Trials of Antiretroviral Regimens: Drawbacks of Not Including Viral Load Measurements after Premature Discontinuation of Therapy. <i>Antiviral Therapy</i> , <b>2002</b> , 7, 271-281	1.6	9
59	Clinical correlation of variations in the internal transcribed spacer regions of rRNA genes in <i>Pneumocystis carinii</i> f.sp. hominis. <i>Aids</i> , <b>2001</b> , 15, 451-9	3.5	43
58	Highly active antiretroviral therapy and coronary heart disease: the need for perspective. <i>Aids</i> , <b>2001</b> , 15 Suppl 5, S193-201	3.5	19
57	Discontinuation of secondary prophylaxis against <i>Pneumocystis carinii</i> pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. <i>New England Journal of Medicine</i> , <b>2001</b> , 344, 168-74	59.2	127
56	Heterogeneity and compartmentalization of <i>Pneumocystis carinii</i> f. sp. hominis genotypes in autopsy lungs. <i>Journal of Clinical Microbiology</i> , <b>2001</b> , 39, 3789-92	9.7	27
55	Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. <i>Journal of Infectious Diseases</i> , <b>2001</b> , 183, 1290-4	7	196
54	Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. <i>Aids</i> , <b>2001</b> , 15, 2385-95	3.5	49
53	Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir. <i>Aids</i> , <b>2001</b> , 15, 999-1008	3.5	6

52	The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. <i>Aids</i> , <b>2001</b> , 15, 201-9	3.5	41
51	Prognostic markers of short-term mortality in AIDS-associated <i>Pneumocystis carinii</i> pneumonia. <i>Chest</i> , <b>2001</b> , 119, 844-51	5.3	49
50	Inhibition of leukocyte entry into the brain by the selectin blocker fucoidin decreases interleukin-1 (IL-1) levels but increases IL-8 levels in cerebrospinal fluid during experimental pneumococcal meningitis in rabbits. <i>Infection and Immunity</i> , <b>2000</b> , 68, 3153-7	3.7	56
49	Virological Failure among Patients on Haart from across Europe: Results from the EuroSIDA Study. <i>Antiviral Therapy</i> , <b>2000</b> , 5, 107-112	1.6	6
48	Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. <i>Aids</i> , <b>1999</b> , 13, 943-50	3.5	271
47	Discontinuation of <i>Pneumocystis carinii</i> pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. <i>Lancet, The</i> , <b>1999</b> , 353, 1293-8	4.0	174
46	Effects of mutations in <i>Pneumocystis carinii</i> dihydropteroate synthase gene on outcome of AIDS-associated <i>P. carinii</i> pneumonia. <i>Lancet, The</i> , <b>1999</b> , 354, 1347-51	4.0	216
45	Regional survival differences across Europe in HIV-positive people: the EuroSIDA study. <i>Aids</i> , <b>1999</b> , 13, 2281-8	3.5	19
44	Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?. <i>Aids</i> , <b>1999</b> , 13, 1647-51	3.5	77
43	Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. <i>Aids</i> , <b>1999</b> , 13, 2075-82	3.5	106
42	A Comparison of Exposure Groups in the EuroSIDA Study: Starting Highly Active Antiretroviral Therapy (HAART), Response to HAART, and Survival. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>1999</b> , 22, 369	3.1	43
41	A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>1999</b> , 22, 369-78	3.1	108
40	Pretreatment with granulocyte colony-stimulating factor attenuates the inflammatory response but not the bacterial load in cerebrospinal fluid during experimental pneumococcal meningitis in rabbits. <i>Infection and Immunity</i> , <b>1999</b> , 67, 3430-6	3.7	16
39	Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. <i>Aids</i> , <b>1999</b> , 13, F9-16	3.5	58
38	The <i>Pneumocystis carinii</i> major surface glycoprotein (MSG): its potential involvement in the pathophysiology of pneumocystosis. <i>FEMS Immunology and Medical Microbiology</i> , <b>1998</b> , 22, 129-34		7
37	Changes in use of antiretroviral therapy in regions of Europe over time. EuroSIDA Study Group. <i>Aids</i> , <b>1998</b> , 12, 2031-9	3.5	42
36	Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1998</b> , 17, 239-44		15
35	Update on <i>Pneumocystis carinii</i> f. sp. <i>hominis</i> typing based on nucleotide sequence variations in internal transcribed spacer regions of rRNA genes. <i>Journal of Clinical Microbiology</i> , <b>1998</b> , 36, 734-41	9.7	113

34	Diagnostic use of PCR for detection of <i>Pneumocystis carinii</i> in oral wash samples. <i>Journal of Clinical Microbiology</i> , <b>1998</b> , 36, 2068-72	9.7	84
33	Human herpes virus-8 DNA in bronchoalveolar lavage samples from patients with AIDS-associated pulmonary Kaposi's sarcoma. <i>Scandinavian Journal of Infectious Diseases</i> , <b>1997</b> , 29, 13-6		15
32	Toxoplasmosis in Danish AIDS patients. <i>Scandinavian Journal of Infectious Diseases</i> , <b>1997</b> , 29, 597-600		11
31	Rapid detection of cytomegalovirus in bronchoalveolar lavage fluid and serum samples by polymerase chain reaction: correlation of virus isolation and clinical outcome for patients with human immunodeficiency virus infection. <i>Clinical Infectious Diseases</i> , <b>1997</b> , 24, 878-83	11.6	3
30	Neutrophil chemotactic activity in bronchoalveolar lavage fluid of patients with AIDS-associated <i>Pneumocystis carinii</i> pneumonia. <i>Scandinavian Journal of Infectious Diseases</i> , <b>1997</b> , 29, 367-71		17
29	Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1997</b> , 16, 153-60		45
28	Factors associated with the CD4+ lymphocyte count at diagnosis of acquired immunodeficiency syndrome. The AIDS IN EUROPE Study Group. <i>Journal of Clinical Epidemiology</i> , <b>1996</b> , 49, 1253-8	5.7	10
27	Newer Therapies for <i>Pneumocystis carinii</i> Pneumonia. <i>Clinical Pulmonary Medicine</i> , <b>1996</b> , 3, 304-313	0.3	4
26	Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years. <i>Aids</i> , <b>1996</b> , 10, 911-918	3.5	37
25	Evaluation of PCR technique for diagnosing <i>Pneumocystis carinii</i> pneumonia in HIV positive patients using oropharyngeal washings. <i>Journal of Eukaryotic Microbiology</i> , <b>1996</b> , 43, 9S	3.6	8
24	Antibody responses to <i>Pneumocystis carinii</i> in hospital personal with and without exposure to patients with <i>P. carinii</i> pneumonia. <i>Journal of Eukaryotic Microbiology</i> , <b>1996</b> , 43, 10S	3.6	4
23	Changes in Survival Over Time After a First Episode of <i>Pneumocystis carinii</i> Pneumonia for European Patients With Acquired Immunodeficiency Syndrome. <i>Archives of Internal Medicine</i> , <b>1995</b> , 155, 822		9
22	Does cytomegalovirus predict a poor prognosis in <i>Pneumocystis carinii</i> pneumonia treated with corticosteroids? A note for caution. <i>Chest</i> , <b>1995</b> , 108, 411-4	5.3	40
21	Prognostic value of interleukin-8 in AIDS-associated <i>Pneumocystis carinii</i> pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>1995</b> , 151, 1058-62	10.2	21
20	Changing patterns of Kaposi's sarcoma in Danish acquired immunodeficiency syndrome patients with complete follow-up. The Danish Study Group for HIV Infection (DASHI). <i>American Journal of Epidemiology</i> , <b>1995</b> , 141, 652-8	3.8	30
19	Does the onset of tuberculosis in AIDS predict shorter survival? Results of a cohort study in 17 European countries over 13 years. AIDS in Europe Study Group. <i>BMJ: British Medical Journal</i> , <b>1995</b> , 311, 1468-71		31
18	PAF receptor antagonists in the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , <b>1994</b> , 3, 733-742	5.9	4
17	A sex comparison of rates of new AIDS-defining disease and death in 2554 AIDS cases. AIDS in Europe Study Group. <i>Aids</i> , <b>1994</b> , 8, 831-5	3.5	39

16	IgM response to a human <i>Pneumocystis carinii</i> surface antigen in HIV-infected patients with pulmonary symptoms. <i>Scandinavian Journal of Infectious Diseases</i> , <b>1993</b> , 25, 515-20		12
15	Serum type III procollagen peptide in patients with <i>Pneumocystis carinii</i> infection. The Copenhagen-Amsterdam PCP-Prednisolone Study Group. <i>The American Review of Respiratory Disease</i> , <b>1993</b> , 148, 1558-62		14
14	Amount of <i>Pneumocystis carinii</i> and degree of acute lung inflammation in HIV-associated <i>P. carinii</i> pneumonia. <i>Chest</i> , <b>1993</b> , 104, 109-13	5:3	22
13	Effects of inhibitors of arachidonic acid metabolism on serotonin release from rat basophilic leukemia cells. <i>Immunopharmacology</i> , <b>1993</b> , 25, 131-44		13
12	Antibody responses to a major <i>Pneumocystis carinii</i> antigen in human immunodeficiency virus-infected patients with and without <i>P. carinii</i> pneumonia. <i>Journal of Infectious Diseases</i> , <b>1992</b> , 165, 1151-5	7	40
11	Substance P and neurokinin A in human nasal mucosa. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>1991</b> , 4, 228-36	5:7	141
10	Platelet-activating factor stimulates eicosanoid production in cultured feline tracheal explants. <i>Experimental Lung Research</i> , <b>1991</b> , 17, 1079-94	2:3	10
9	HIV-associated lymphoma: histopathology and association with Epstein-Barr virus genome related to clinical, immunological and prognostic features. <i>European Journal of Cancer &amp; Clinical Oncology</i> , <b>1991</b> , 27, 1416-23		61
8	Pathogenesis of airway mucus hypersecretion. <i>Journal of Allergy and Clinical Immunology</i> , <b>1990</b> , 85, 399-417		103
7	Substance P receptor-mediated secretion of respiratory glycoconjugate from feline airways in vitro. <i>Experimental Lung Research</i> , <b>1989</b> , 15, 17-29	2:3	35
6	The whole-mount method as a technique for measuring experimental changes in airway goblet cell number. <i>Apmis</i> , <b>1989</b> , 97, 1141-5	3:4	5
5	Dexamethasone reduces rat tracheal goblet cell hyperplasia produced by human neutrophil products. <i>Experimental Lung Research</i> , <b>1988</b> , 14, 853-63	2:3	43
4	Dexamethasone inhibits respiratory glycoconjugate secretion from feline airways in vitro by the induction of lipocortin (lipomodulin) synthesis. <i>The American Review of Respiratory Disease</i> , <b>1988</b> , 137, 353-7		59
3	The effects of endorphins on mucous glycoprotein secretion from feline airways in vitro. <i>Experimental Lung Research</i> , <b>1987</b> , 12, 303-9	2:3	8
2	XVI. The <i>Pneumocystis carinii</i> major surface glycoprotein (MSG): its potential involvement in the pathophysiology of pneumocystosis		2
1	Clinical and Virological Response to a Neutralizing Monoclonal Antibody for Hospitalized Patients with COVID-19		2